Community News: Ozarks Healthcare Therapies gifts wheelchair to pediatric patient courtesy of Zechman Fund (9/15/21) areawidenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from areawidenews.com Daily Mail and Mail on Sunday newspapers.
The drug maker has secured a tentative approval from the US drug regulator to market Brivaracetam tablets, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg.
Brivaracetam is used to treat partial-onset of seizures (epilepsy). The drug will be manufactured at the Zydus Cadila group s formulation manufacturing facility at the SEZ, Ahmedabad (Gujarat).
The group currently received 319 approvals and has filed over 400 ANDAs since the commencement of the filing process in FY 2003-04. The announcement was made before market hours today, 14 June 2021.
On a consolidated basis, the drug maker s net profit surged 76.9% to Rs 731.60 crore on 3.6% increase in net sales to Rs 3,756.20 crore in Q4 March 2021 over Q4 March 2020.
Read more about Cadila Healthcare gets USFDA nod for lung cancer drug on Business Standard. The drug major has received tentative approval from the US drug regulator to market osimertinib tablets in the strengths of 40 mg and 80 mg.
On a consolidated basis, the drug maker s net profit surged 73.25% to Rs 679 crore on 2.52% increase in total revenue from operations to Rs 3,846.70 crore in Q4 March 2021 over Q4 March 2020.
Profit before exceptional items, tax and share of profit of joint ventures rose 5% year-on-year to Rs 603.10 crore in Q4 FY21. EBIDTA grew by 8% to Rs 855 crore during the fourth quarter from the same quarter, last year.
During the financial year, Cadila Healthcare s net profit spurted 81.33% to Rs 2,133.60 crore on 5.95% rise in total revenue from operations to Rs 15,102.20 crore in FY 2021 over FY 2020. The EBIDTA for the year stood at Rs 3,341 crore, registering 20% growth over the previous year.
Cadila Healthcare rose 2.60% to Rs 646.10 after the company s subsidiary announced plans to sell its India focused animal health business to Multiples Alternate Asset Management led consortium.
Zydus Animal Health and Investments (ZAHL), a wholly owned material subsidiary of Cadila Healthcare, has entered into a business transfer agreement (BTA) and other ancillary agreements to sell and transfer its Animal Healthcare Established Markets Undertaking (Zydus AH) to Multiples Alternate Asset Management led consortium.
The deal is to sell one of the two business undertakings of ZAHL, called Animal Healthcare Established Markets Undertaking on a slump sale basis as a going concern, for a lump sum consideration of Rs 2,921 crore on a cash free and debt free basis, subject to certain closing date adjustments and other conditions.